Table 1 Patient characteristics at initiation of HD (n = 166)
From: Lower Hb at the initiation of dialysis does not adversely affect 1-year mortality rate
Clinical findings | |
Age (years) | 61.5 ± 14.3(30~89) |
Gender (male/female) | 110/56 |
Systolic/diastolic blood pressure (mmHg) | 147 ± 21/76 ± 16 |
BW (kg; mean ± SD) | 62.6 ± 15.7 |
Method of HD initiation (AVF/catheter) | 125/41 |
Primary disease of ESKD | |
Diabetic nephropathy | 87 (49%) |
Chronic glomerulonephritis | 13 (8%) |
Nephrosclerosis | 41 (25%) |
Polycystic kidney disease | 4 (2.4%) |
Others | 21 (12.7%) |
Laboratory findings | |
Hb (g/dL) | 8.56 ± 1.3 |
Fe/TIBC (μg/dL) | 61 ± 31/212 ± 44 |
Ferritin (ng/dL) | 305 ± 315 |
Serum albumin (g/dL) | 3.0 ± 0.6 |
BUN/creatinine (mg/dL) | 103 ± 33/11.1 ± 4.3 |
eGFR (mL/m/1.73m2) | 4.5 ± 1.8 |
K (mEq/L) | 4.7 ± 1.0 |
Ca/P (mg/dL) | 8.5 ± 1.1/7.6 ± 2.1 |
Intact PTH(pg/mL) | 186 ± 107 |
B-type natriuretic peptide (BNP) (ng/mL) | 954 ± 2136 (4~18258) |
Cardiothoracic rate (CTR) (%) | 54.8 ± 6.0 |
ESA treatment | 129 (78%) epoetin beta pegol:89 darbepoetin:40 |
ESA dosage (U/week; converted in Epo dosage) | 4871 ± 3259 |
Erythropoietin resistance index(U/week/Hb (g/dL) × BW (kg)) | 9.95 ± 7.36 |
Fe treatment | 46 (28%) |